A randomized trial supports the recommendation to continue treatment with ACEi or ARBs during hospitalization for COVID-19
Eur Heart J
.
2021 Mar 14;42(11):1061-1062.
doi: 10.1093/eurheartj/ehab106.
Authors
Massimo Volpe
1
,
Carlo Patrono
2
Affiliations
1
Cardiology, Sapienza University of Rome, Sant'Andrea Hospital, Rome, Italy.
2
Pharmacology, Catholic University School of Medicine, Rome, Italy and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
PMID:
33659979
PMCID:
PMC7989525
DOI:
10.1093/eurheartj/ehab106
No abstract available
Publication types
Comment
MeSH terms
Angiotensin Receptor Antagonists*
Angiotensin-Converting Enzyme Inhibitors
COVID-19*
Hospitalization
Hospitals
Humans
SARS-CoV-2
Substances
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors